Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-5339 in R/R AML or MDS
NCT04402541Phase 1Completed
- Sponsor
- Cleave Therapeutics
- Start
- Jun 2020
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of CB-5339 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Cleave Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events and serious adverse events at 28 Days and Maximum Tolerated Dose and/or Recommended Phase 2 Dose at 28 Days. Started Jun 2020; status: completed.
02
Drugs
CB-5339
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04402541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04402541.